Skip to main content

Table 1 Clinical characteristics of survivors

From: An assessment of quality of life for early phase after adjuvant radiotherapy in breast cancer survivors: a Korean multicenter survey (KROG 14–09)

  1st year group 2nd year group 3rd year group  
N (%) N (%) N (%) p valuea)
Age (years) Median 50.0 51.8 52.1 0.010
  <41 63 (10.8) 23 (7.0) 15 (6.5)  
  41–50 255 (43.8) 126 (38.2) 88 (38.3)  
  51–60 205 (35.2) 132 (40.0) 87 (37.8)  
  >60 59 (10.1) 49 (14.8) 40 (17.4)  
Stage of disease     0.105
  0 86 (14.7) 37 (11.2) 28 (12.1)  
  I 250 (42.8) 156 (47.4) 107 (46.3)  
  II 190 (32.5) 101 (30.6) 60 (26.0)  
  III-IV 58 (9.9) 35 (10.6) 36 (15.6)  
Menstrual status     0.383
  Premenopausal 350 (60.1) 195 (59.0) 148 (64.6)  
  Postmenopausal 232 (39.9) 135 (40.9) 81 (35.4)  
Breast surgery     0.630
  Breast-conserving surgery 541 (92.6) 302 (91.2) 210 (90.9)  
  Mastectomy 43 (7.4) 29 (8.8) 21 (9.1)  
Axillary surgery     0.206
  None 62 (10.7) 27 (8.2) 25 (10.9)  
  Sentinel node dissection 293 (50.3) 190 (57.4) 128 (55.9)  
  Axillary node dissection 227 (39.0) 114 (27.3) 76 (33.2)  
Radiotherapy field     0.905
  Breast only 435 (74.4) 251 (75.6) 174 (75.3)  
  Breast and regional nodes 150 (25.6) 81 (24.4) 57 (24.7)  
Chemotherapy     0.469
  No 211 (36.3) 125 (37.8) 75 (32.8)  
  Yes 371 (63.7) 206 (62.2) 154 (67.2)  
Hormone therapy     <0.001
  No 163 (29.1) 64 (19.5) 43 (18.6)  
  Yes 397 (70.9) 265 (80.5) 188 (81.4)  
Target therapy     0.855
  No 507 (88.9) 294 (89.4) 203 (87.9)  
  Yes 63 (11.1) 35 (10.6) 28 (12.1)  
  1. a)Pearson’s Chi-square test